Biology Reference
In-Depth Information
reperfusion, T lymphocytes, and Nox2-derived
superoxide. J Cereb Blood Flow Metab
30:1306-1317
43. Alkayed NJ et al (1998) Gender-linked brain
injury in experimental stroke. Stroke 29:159-
165, discussion 166
44. Bouley J, Fisher M, Henninger N (2007)
Comparison between coated vs. uncoated
suture middle cerebral artery occlusion in the
rat as assessed by perfusion/diffusion weighted
imaging. Neurosci Lett 412:185-190
45. Spratt NJ et al (2006) Modification of the
method of thread manufacture improves stroke
induction rate and reduces mortality after
thread-occlusion of the middle cerebral artery
in young or aged rats. J Neurosci Methods
155:285-290
46. Chuquet J et al (2008) Effects of urotensin-II
on cerebral blood flow and ischemia in anes-
thetized rats. Exp Neurol 210:577-584
47. Lecrux C et al (2007) Spontaneously hyper-
tensive rats are highly vulnerable to AMPA-
induced brain lesions. Stroke 38:3007-3015
48. Esneault E et al (2008) Combined therapeutic
strategy using erythropoietin and mesenchy-
mal stem cells potentiates neurogenesis after
transient focal cerebral ischemia in rats. J Cereb
Blood Flow Metab 28:1552-1563
49. Esneault E et al (2008) D-JNKi, a peptide
inhibitor of c-Jun N-terminal kinase, promotes
functional recovery after transient focal cerebral
ischemia in rats. Neuroscience 152:308-320
50. Kuraoka M et al (2009) Direct experimental
occlusion of the distal middle cerebral artery
induces high reproducibility of brain ischemia
in mice. Exp Anim 58:19-29
51. G-ming X et al (2004) Evaluation of murine
models of permanent focal cerebral ischemia.
Chin Med J 117:389-394
52. Fotheringham AP, Davies CA, Davies I (2000)
Oedema and glial cell involvement in the aged
mouse brain after permanent focal ischaemia.
Neuropathol Appl Neurobiol 26:412-423
53. Taguchi A et al (2010) A reproducible and
simple model of permanent cerebral ischemia
in CB-17 and SCID mice. J Exp Stroke Transl
Med 3:28-33
54. Freret T et al (2011) On the importance of
long-term functional assessment after stroke to
improve translation from bench to bedside.
Exp Transl Stroke Med 3:6
55. Garcia JH et al (1995) Neurological deficit
and extent of neuronal necrosis attributable to
middle cerebral artery occlusion in rats: statis-
tical validation. Stroke 26:627-635
56. Brines ML et al (2000) Erythropoietin crosses
the blood-brain barrier to protect against
experimental brain injury. Proc Natl Acad Sci
U S A 97:10526-10531
57. Bernaudin M et al (1999) A potential role for
erythropoietin in focal permanent cerebral
ischemia in mice. J Cereb Blood Flow Metab
19:643-651
58. Eid T, Brines M (2002) Recombinant human
erythropoietin for neuroprotection: what is
the evidence? Clin Breast Cancer 3(Suppl
3):S109-S115
59. Digicaylioglu M (2010) Erythropoietin in
stroke: quo vadis. Expert Opin Biol Ther
10:937-949
60. Ehrenreich H et al (2009) Recombinant
human erythropoietin in the treatment of
acute ischemic stroke. Stroke 40:e647-e656
61. Ehrenreich H et al (2004) Erythropoietin:
novel approaches to neuroprotection in human
brain disease. Metab Brain Dis 19:195-206
62. Jerndal M et al (2010) A systematic review and
meta-analysis of erythropoietin in experimen-
tal stroke. J Cereb Blood Flow Metab 30:961-
968. doi:
10.1038/jcbfm.2009.267
63. Erbayraktar S et al (2003) Asialoerythropoietin
is a nonerythropoietic cytokine with broad
neuroprotective activity in vivo. Proc Natl
Acad Sci U S A 100:6741-6746
64. Sirén AL et al (2001) Erythropoietin prevents
neuronal apoptosis after cerebral ischemia and
metabolic stress. Proc Natl Acad Sci U S A
98:4044-4049
65. Villa P et al (2003) Erythropoietin selectively
attenuates cytokine production and
inflammation in cerebral ischemia by targeting
neuronal apoptosis. J Exp Med 198:971-975
66. Wang L et al (2004) Treatment of stroke with
erythropoietin enhances neurogenesis and
angiogenesis and improves neurological func-
tion in rats. Stroke 35:1732-1737
67. Ghezzi P, Brines M (2004) Erythropoietin as
an antiapoptotic, tissue-protective cytokine.
Cell Death Differ 11(Suppl 1):S37-S44
68. Ehrenreich H et al (2002) Erythropoietin
therapy for acute stroke is both safe and
beneficial. Mol Med 8:495-505
69. Brines M et al (2008) Nonerythropoietic, tis-
sue-protective peptides derived from the ter-
tiary structure of erythropoietin. Proc Natl
Acad Sci U S A 105:10925-10930
70. Hermann DM (2010) Nonhematopoietic vari-
ants of erythropoietin in ischemic stroke: need
for step-wise proof-of-concept studies.
ScientificWorldJournal 10:2285-2287
71. Villa P et al (2007) Reduced functional deficits,
neuroinflammation, and secondary tissue dam-
age after treatment of stroke by nonerythro-
poietic erythropoietin derivatives. J Cereb
Blood Flow Metab 27:552-563
72. Hermann DM (2009) Enhancing the delivery
of erythropoietin and its variants into the isch-
emic brain. ScientificWorldJournal 9:967-969
Search WWH ::
Custom Search